The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health (NIH) to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2.
The network is seeking the assistance of pharmacists and pharmacy personnel to inform the public of the opportunity to participate in the clinical trials. More information and the link to volunteer can be found at the COVID-19 Prevent Network website.
There are materials available to pharmacists that can be used to share with patients, communities, family and friends. A special referral code (RXRX) has been created for individuals to include when signing up that identifies pharmacy as the source of referral and demonstrate pharmacy’s impact.
The development and release of effective vaccines against COVID-19 is dependent upon recruiting sufficient numbers of individuals to participate in the vaccine clinical trials, especially individuals within these targeted demographics:
- People with underlying medical conditions
- People with greater chances of exposure at their job
- People who live or work in elder-care facilities
- People over age 65
- People who work in jails or prisons
- People from racial and ethnic groups that have been impacted in greater numbers by the epidemic, such as African Americans, Latinx, and Native Americans
Individuals interested in volunteering complete a short online survey that includes some personal questions and entry into a registry. The purpose of the screening registry is to create a list of potential volunteers who want to take part in current or future COVID-19 prevention clinical trials. Individuals must be 18 years or older to participate. Participation is voluntary.
COVID-19 prevention study participants will be compensated for their time. COVID-19 prevention study participants CANNOT get infected with SARS-CoV-2 or get COVID-19 illness from the study vaccine.